Tesamorelin
An FDA-approved stabilized GHRH analog used to reduce visceral fat, with broader interest in body composition and cognition research.
Overview
Tesamorelin is a synthetic GHRH analog approved for HIV-associated lipodystrophy. Its stable structure supports daily subcutaneous dosing, and it has gained interest beyond its label for stubborn visceral fat reduction and possible cognitive support in aging populations.
Benefits
- Targets visceral adipose tissue specifically
- Raises endogenous GH and IGF-1
- May improve cognition in older adults
- FDA-approved with established safety profile
Mechanism of Action
Tesamorelin binds GHRH receptors on the anterior pituitary, triggering pulsatile endogenous GH release. The resulting GH/IGF-1 elevation drives lipolysis, particularly in visceral fat depots.
Dosage (informational only)
- Typical range
- 1–2 mg per day
- Frequency
- Daily subcutaneous administration
Approved at 2 mg daily. May affect glucose tolerance — monitoring is advised.
Side Effects
- Injection site reactions
- Joint pain or fluid retention
- Possible glucose intolerance
- Transient elevations in IGF-1
Related peptides
A selective ghrelin receptor agonist that triggers clean, pulsatile GH release without significant cortisol or prolactin spikes.
A non-peptide ghrelin mimetic taken orally to elevate GH and IGF-1 over a 24-hour window.
A GHRH (1–29) analog that stimulates the body's natural growth hormone production through normal pituitary feedback.